Why It Matters
The American College of Medical Genetics and Genomics (ACMG) ended its in-house lobbying registration at the close of the second quarter, concluding what had been a modest advocacy effort on behalf of the genetic testing industry.
The organization reported $30,000 in lobbying spending activities during the second quarter of 2026, before terminating its in-house lobbying registration effective Tuesday, June 30.
Broader Context
The termination reflected what had been a relatively limited in-house advocacy operation. The organization's quarterly expenditure of thirty thousand dollars suggests a scaled operation compared to major industry players that spend substantially larger sums on federal advocacy.
The American College of Medical Genetics lobbying operation was managed by David Molina, the organization's Advocacy Manager. Molina brings relevant congressional experience to the role, having previously worked with former Rep. Alan Lowenthal (D-CA-47).
The termination of ACMG's in-house advocacy operation occurs against a backdrop of evolving congressional interest in genetic testing practices. This decision may reflect broader shifts in how professional medical organizations approach federal advocacy.
The termination also suggests the organization determined that its legislative priorities could be addressed through alternative advocacy structures or that the return on direct lobbying investment did not justify maintaining the in-house operation.
The Bottom Line
The ACMG lobbying termination becomes part of a broader pattern in how professional medical organizations structure their federal affairs operations. The decision to close out the in-house registration effective at the end of the second quarter represents a clear shift in the organization's approach to direct legislative engagement.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article